Hydroxyurea is a once-a-day pill that has become standard treatment for sickle cell anaemia in wealthy countries. In the part of the world where the disease is most common, doctors have been slower to prescribe it, held back by a specific fear. The drug lowers the number of neutrophils, white blood cells that fight infection, and in places where malaria is endemic and clinical care can be far away, that looked like a dangerous trade.
A study published in The Lancet Haematology suggests the fear is unfounded. Following 606 children and young adults at sites in Angola, the Democratic Republic of the Congo, Kenya and Uganda for roughly a decade, researchers found no increase in the incidence or severity of clinically diagnosed infections among those taking hydroxyurea. As doses went up, infections went down.
Across more than 5,000 patient-years of follow-up, there was “no increase of illness or death from infections,” even at the highest dose patients could tolerate, said Tom Williams, a professor at Imperial College London’s Institute of Global Health Innovation, who led the study.
A Disease Concentrated in Africa
Sickle cell anaemia is the most common severe inherited blood disorder in humans. About 550,000 children are born with it every year, and roughly 80 percent of cases occur in sub-Saharan Africa. It causes episodes of intense pain, chronic ill health and a heightened vulnerability to bacterial and viral infections, which are frequent in these children and can kill.
Hydroxyurea works by prompting the body to produce more fetal haemoglobin, the form made in the womb. Fetal haemoglobin keeps red blood cells from bending into the rigid sickle shape that blocks small blood vessels and drives the disease’s complications.
The theoretical worry was that by suppressing neutrophils, the drug would dampen immunity and make infections, malaria among them, more common or more severe. Until now that possibility had not been examined in detail in the settings where it mattered most.
Ten Years of Follow-Up
The analysis comes from REACH, a trial funded by the U.S. National Institutes of Health that has been running for more than ten years. Children between the ages of one and ten were enrolled from 2014 to 2016 and have been seen every two to three months since. Each began hydroxyurea at a fixed dose for six months and was then moved up to the maximum dose they could tolerate.
Earlier results from REACH had already shown that the drug is safe in these settings and highly effective at reducing most complications of sickle cell disease. The extended analysis turned to infections. The incidence of infection fell as the dose rose. The risk of malaria dropped by 51 percent and the risk of non-malarial infections by 38 percent.
Russell Ware, a professor at Cincinnati Children’s Hospital Medical Center and the study’s senior author, said the findings supply long-awaited evidence on the long-term safety of maximum-dose hydroxyurea in low-income settings. Over ten years of treatment, he noted, infections did not increase and in many cases became less frequent.
Reading the Numbers Carefully
The study has a limitation the researchers acknowledge. Most infections were recorded retrospectively from each child’s clinical history, not confirmed by laboratory testing at the time. The work is also a cohort study drawn from a trial in which every participant received the drug, so the falling infection rates are an association with rising dose, not a comparison against untreated children. Children also grow older over a decade, and age alone changes infection risk.
What the data do speak to directly is the safety question, which was whether infections would get worse. They did not. On that basis the authors recommend that children with sickle cell anaemia in low-resource settings be treated with hydroxyurea at the maximum tolerated dose.
Williams said the results offer strong reassurance that neither long-term use nor the highest dose increases the incidence or severity of infections, and that they support making hydroxyurea a standard of care much more widely. The research was funded by the National Heart, Lung and Blood Institute and the Cincinnati Children’s Research Foundation.
Endnotes
- “Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a cohort study from the REACH trial.” (October 7, 2026). The Lancet Haematology.
- Imperial College London (October 7, 2026). “Children living with sickle cell can be treated safely using hydroxyurea.” EurekAlert! https://www.eurekalert.org/news-releases/1146717
Featured image: Sickled red blood cells. Credit: Ed Uthman.




Leave a Reply